Welcome to our dedicated page for BIO-PATH HOLDINGS news (Ticker: BPTH), a resource for investors and traders seeking the latest updates and insights on BIO-PATH HOLDINGS stock.
Bio-Path Holdings develops targeted nucleic acid drug candidates using its DNAbilize® liposomal delivery and antisense RNAi nanoparticle technology. Its disclosed pipeline includes prexigebersen (BP1001), which targets Grb2 for blood cancers; BP1001-A, a modified prexigebersen candidate studied in solid tumors and metabolic disease models; BP1002, which targets Bcl-2 for blood cancers and solid tumors; and a STAT3 antisense program.
Company news commonly covers clinical and preclinical program updates, obesity and Type 2 diabetes research, acute myeloid leukemia and other oncology studies, patent grants tied to DNAbilize®, financial results, investor presentations, and corporate or operational updates affecting the biotechnology portfolio.
Bio-Path Holdings (NASDAQ: BPTH) announced encouraging Q1 2021 financial results with a net loss of $2.4 million ($0.43 per share), an improvement from $3.3 million ($0.90 per share) in Q1 2020. The company successfully completed the safety run-in of Stage 2 in its Phase 2 clinical trial for prexigebersen in treating acute myeloid leukemia (AML). Additionally, Bio-Path raised $13 million in a public offering, significantly increasing cash reserves to $30.8 million. Recent data presentations at notable conferences have bolstered awareness of its DNAbilize platform for cancer treatment.
Bio-Path Holdings, Inc. (NASDAQ: BPTH) announced a live conference call and audio webcast scheduled for May 14, 2021, at 8:30 a.m. ET to discuss its financial results for Q1 2021, which ended on March 31, 2021, along with a business overview. The company's proprietary DNAbilize® antisense RNAi nanoparticle technology is being utilized to develop targeted cancer drugs, including its lead candidate, prexigebersen, currently in Phase 2 trials for blood cancers. This event will be accessible via phone or on the company's website.
Bio-Path Holdings announced the publication of a peer-reviewed article in Biomedicines, discussing challenges in antisense oligonucleotide drug delivery and highlighting the advantages of prexigebersen (BP1001). The authors emphasized prexigebersen's potential to address delivery challenges due to its unique properties, including stability and non-toxicity. Currently, prexigebersen is in a Phase 2 study targeting blood cancers, while a modified version is being considered for Phase 1 studies in solid tumors. The breakthrough technology could significantly enhance cancer treatment.
Bio-Path Holdings (NASDAQ: BPTH) announced preclinical data on BP1002, a novel antisense therapy targeting Bcl-2, at the AACR Annual Meeting on April 12, 2021. The study highlighted its efficacy in overcoming venetoclax resistance in acute myeloid leukemia (AML) patients. CEO Peter Nielsen expressed optimism for filing a second Investigational New Drug (IND) application and initiating clinical studies. With median survival under 3 months for relapsed patients, BP1002 represents a critical advancement for treatment options in this vulnerable group.
Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced the successful completion of the safety run-in phase of Stage 2 in its Phase 2 clinical study for prexigebersen (BP1001), targeting acute myeloid leukemia (AML). Six evaluable patients received the triple combination therapy of prexigebersen, decitabine, and venetoclax, with a favorable safety profile and no dose-limiting toxicities. Notably, 83% of patients demonstrated clinical activity. The trial continues enrolling patients, aiming for significant efficacy data to petition the FDA for accelerated approval.
Bio-Path Holdings (NASDAQ: BPTH) announced a virtual poster presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting from April 10-15 and May 17-21, 2021. Dr. Maria Gagliardi will present pre-clinical studies of BP1002 combined with decitabine, targeting venetoclax-resistant cancer cells.
Presentation Details:
Date: April 10, 2021
Time: 8:30 am ET
Session: Biological Therapeutic Agents
Abstract Number: 939
Title: Efficacy of BP1002 with decitabine in resistant cells.
Bio-Path Holdings (NASDAQ:BPTH) announced its financial results for 2020, reporting a net loss of $10.9 million, or $2.83 per share, compared to a loss of $8.6 million in 2019. Research and development expenses rose to $6.6 million from $4.6 million, reflecting increased clinical activity. The company raised $13 million through a public offering and secured a new U.S. patent for its DNAbilize® platform technology. Bio-Path commenced a Phase 1 trial for BP1002.
Bio-Path Holdings (NASDAQ: BPTH) will host a live conference call on March 10, 2021, at 8:30 a.m. ET to report its financial results for 2020 and provide a business overview. The call can be accessed at (844) 815-4963 domestically or (210) 229-8838 internationally, using conference ID 6296959. Additionally, a live audio webcast will be available on the company's website. Bio-Path focuses on developing its proprietary DNAbilize® technology for targeted nucleic acid cancer treatments. Key products include prexigebersen, in Phase 2 trials for blood cancers, and BP1002, under evaluation for lymphoma.
Bio-Path Holdings, Inc. (Nasdaq:BPTH) has successfully closed its public offering of 1,710,600 shares of common stock at $7.60 each, raising approximately $13.0 million before fees. Proceeds are intended for working capital and general corporate purposes. Roth Capital Partners served as the sole placement agent for the offering. The shares were offered under an effective shelf registration statement, and the company is developing novel cancer treatments utilizing its DNAbilize® technology, targeting specific protein pathways.
Bio-Path Holdings, Inc. (Nasdaq:BPTH) announced a public offering of 1,710,600 shares at $7.60 each, raising approximately $13 million before expenses. The offering is expected to close on February 18, 2021. Proceeds will be utilized for working capital and general corporate purposes. Roth Capital Partners is the sole placement agent for this offering. A registration statement related to the shares has been declared effective by the SEC. Bio-Path is advancing its DNAbilize® technology aimed at developing targeted cancer drugs, including prexigebersen currently in Phase 2 studies.